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Summary The etiology of esophageal mucosal injury is complex, since it may involve the
reflux of gastric acid, bile acid, and pancreatic juice, external factors such as drugs and alcohol,
or functional factors such as esophagogastric motility. The mechanism of esophageal mucosal
injury has gradually been understood at the molecular biological level. It is particularly
important that pro-inflammatory factors, such as inflammatory cytokines (interleukin-6 and
-8), leukocytes and oxidative stress, have been demonstrated to be involved in the development
of gastroesophageal reflux disease (GERD) including nonerosive reflux disease (NERD). In
addition, nociceptors such as acid-sensitive vanilloid receptors, protease-activated receptors
and substance P have also been implicated in the pathogenesis of neurogenic inflammation in
NERD patients with esophageal hypersensitivity. The development of new therapy with anti-
inflammatory and anti-oxidant effects is expected to assist in the treatment of intractable
NERD/GERD and the prevention of carcinogenesis.
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Introduction
Gastroesophageal reflux disease (GERD), which is induced
by reflux of the gastric and duodenal contents into the
esophagus, has recently come to be recognized as a serious
clinical problem and the number of patients has been
increasing. GERD significantly affects the quality of life
because of associated symptoms, such as pharyngeal pain,
chest pain, chronic cough, and asthma, as well as typical
reflux symptoms such as heartburn. It has been reported that
the psychological burden of patients with GERD is heavier
than that of patients with duodenal ulcer or angina pectoris
[1]. The occurrence of GERD is closely related to relaxation
of the lower esophageal sphincter (LES) and increased
gastric acid secretion, both of which are associated with
westernization of the lifestyle and diet (a high-fat diet), as
well as an increase of geriatric patients with hernia and a
decreased prevalence of Helicobacter pylori infection.
GERD is classified into two types based on the endoscopic
detection of mucosal lesions (such as erosions), which are
endoscopically positive GERD and endoscopically negative
GERD. The former type of GERD is known as reflux esoph-
agitis and the latter is almost synonymous with nonerosive
GERD (NERD) or (narrowly defined) symptomatic GERD
(s-GERD). Based on the mechanism of GERD, proton pump
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inhibitors (PPI), which are strong inhibitors of acid secretion,
are the first-line drugs for its treatment. However, several
issues remain controversial, such as the pathogenesis of
NERD as a functional disorder, the recurrence and poor
curability of GERD, the progression and prognosis of Barrett’s
epithelium, and the relationship between eradication of
Helicobacter pylori infection and GERD.
In the clinical setting, patients with NERD account for
60 to 70% of those with GERD and symptoms such as
heartburn have become a major clinical concern. To develop
effective treatment strategies for GERD and to estimate the
long-term prognosis of this disease, it is very important
to understand the mechanism of its development. Although
GERD has been examined thoroughly under physiological
conditions (e.g., investigation of acid reflux into the esophagus
by pH monitoring, measurement of intraesophageal pressure,
and observation of peristalsis in the esophagus), leading to
the accumulation of important knowledge, biochemical and
molecular biological studies of the esophageal mucosa
remain far behind in comparison with other digestive organs.
Studies of esophagitis that have focused on factors related
to inflammation, such as oxidative stress, chemokines, inflam-
matory cells, and growth factors, have increasingly drawn
attention to a new approach to GERD as an inflammatory
disease. With regard to NERD as a functional disorder,
investigations are already focusing on factors related to
sensory abnormalities, such as neuropeptides, acid sensors,
and baroreceptors. In this article, we review the significance
of inflammatory factors, such as cytokines, oxidative stress
and neuropeptides, in the pathogenesis of GERD, the anti-
inflammatory and anti-oxidative actions of PPI, mucosal
protective agents and protease inhibitors for the treatment
of esophageal mucosal injury in human and experimental
animals.
Esophageal Mucosal Resistance (Fig. 1)
The esophageal mucosa is formed by stratified squamous
Fig. 1.  Esophageal mucosal resistance. The defense mechanism of the esophageal mucosa, which consists of stratified squamous epi-
thelium, is composed of superficial pre-epithelial, epithelial, and deep post-epithelial mechanisms.Oxidative Stress in GERD
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epithelium that consists of 20 to 30 layers of cells. It is
composed of three functionally distinct layers-the stratum
corneum, the stratum spinosum and the stratum germi-
nativum. Cells divide above the basement membrane and
are transformed morphologically and functionally while
moving from the stratum germinativum to layers closer to
the esophageal lumen, such as stratum spinosum and stratum
corneum. The stratum corneum forms a barrier, the stratum
spinosum contains cells with a high metabolic activity, and
the stratum germinativum is composed of one to two layers
of dividing cells located on the basement membrane. Cells
move towards the lumen of the esophagus and are eventually
sloughed. The half-life of this cycle is reported to be 7
days in rats [2]. Theoretically, the esophageal mucosa has
three defense mechanisms, i.e., 1) a pre-epithelial defense
mechanism consisting of mucus, bicarbonate ion, and
epithelial growth factors, 2) an epithelial defense mechanism
consisting of the epithelial cells and intercellular junctional
complexes, and 3) a post-epithelial defense mechanism
consisting of blood vessels. The pre-epithelial superficial
defense mechanism is not very strong, so esophageal epithelial
cells are easily exposed to refluxed acid and duodenal juice
[3].
Mucosal Inflammation in GERD
Cytokines and oxidative stress in GERD patients
It has recently been demonstrated that inflammatory
cytokines, including chemokines, play an important role in
inducing early inflammatory changes in patients with GERD.
Using esophageal biopsy samples obtained from patients
with GERD (including those with NERD), we examined
correlations between the expression of various genes (inter-
leukin (IL)-6, IL-8, and monocyte chemoattractant protein 1
(MCP-1)) and the endoscopic findings, histological findings,
and symptoms. We found that IL-8 mRNA levels in the
esophageal mucosa of patients with GERD were signifi-
cantly higher than in normal subjects [3, 4]. Regarding the
expression of IL-8 mRNA, there was a positive correlation
with endoscopic severity (Fig. 2) as well as with the histo-
logical neutrophil infiltration score, but there was no clear
correlation with the QUEST score (an index of the severity
of symptoms). Although an increase of IL-6 (Fig. 3) and
MCP-1 was also observed in patients with GERD or NERD,
no correlation was detected between the expression of these
genes and endoscopic severity. Immunostaining analysis
revealed that expression of IL-8 was primarily localized
to the basal layer of the esophageal epithelium in patients
with GERD. IL-8 is a neutrophil-activating factor that is
chiefly produced by leukocytes and vascular endothelial cells.
The results of our investigation indicated that esophageal
epithelium cells play an important role in the development
of mucosal inflammation by producing IL-8. In patients
Fig. 2.  Relationship between IL-8 mRNA expression and the
endoscopic grade of gastroesophageal reflux disease
(GERD) (4). Samples were taken from mucosal breaks
in patients with esophagitis. Expression of IL-8 mRNA
was quatified by real-time polymerase chain reaction
(PCR) using biopsy mucosal materials and was corrected
for that of GAPDH mRNA. Endoscopic grading was
done according to the Los Angeles (LA) classification.
Reprinted with permission [4].
Fig. 3.  IL-6 mRNA expression in esophageal mucosa from
patients with GERD. Samples were taken from mucosal
breaks in patients with esophagitis. Expression of IL-6
mRNA was quantified and analyzed in the same manner
as described in the Fig. 2. *P<0.05 versus normal control.N. Yoshida
J. Clin. Biochem. Nutr.
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treated with oral PPI therapy for 8 weeks, IL-8 mRNA levels
declined quickly as both symptoms and endoscopic findings
improved, but there was no change of MCP-1 mRNA levels.
These observations indicate that IL-8 is a sensitive marker of
esophageal inflammation.
Interestingly, our study detected IL-8 in all of the patients
with NERD and IL-8 gene expression in these patients
was significantly increased compared with that in normal
subjects, although it was still lower than in patients with
endoscopically positive GERD. In addition, slight neutrophil
infiltration into the esophageal mucosa was observed in 50%
of the patients with NERD. These observations indicate that
some patients with NERD may have mild inflammatory
changes, which are macroscopically invisible, of the sub-
epithelial region. In fact, detailed analysis of gene expression
using a DNA microarray has revealed elevated levels of
inflammatory cytokines, such as tumor necrosis factor,
interferon  α, IL-1, IL-6 and IL-8, in biopsy specimens
obtained from NERD patients (Table) [5].
Isomoto et al. [6] reported that chemokines have a role
in the pathology of reflux esophagitis. Marked elevation of
the levels of IL-8, MCP-1, and RANTES (regulated on
activation normal T-cell expressed and presumably secreted)
has been observed in the esophageal mucosa of patients with
reflux esophagitis. Thickening of the basement membrane is
correlated with the expression of IL-8 and MCP-1, while
the infiltration of neutrophils and eosinophils into the
esophageal mucosa is correlated with the expression of IL-8
and RANTES.
Fitzgerald et al. [7] examined the pathological differences
Table Transcriptome analysis of inflammatory cytokines in esophageal mucosa from patients with non-erosive reflux
disease (NERD)
Probe ID NERD Normal Ratio Gene Title
204470_at 343.4 21.3 19.70 chemokine (C-X-C motif) ligand 2
205476_at 1877.3 217.9 14.93 chemokine (C-C motif) ligand 20
207850_at 1036.9 85.2 12.13 chemokine (C-X-C motif) ligand 3
209774_x_at 2321.4 273.5 10.56 chemokine (C-X-C motif) ligand 2
211338_at 18.6 5.7 4.29 interferon, alpha 2 /// interferon, alpha 2
206508_at 191.5 48.7 3.73 tumor necrosis factor (ligand) superfamily, member 7
210118_s_at 2570.1 555.8 3.48 interleukin 1, alpha
1557908_at 97.7 39.1 2.83 toll-interleukin 1 receptor (TIR)
243977_at 315.6 147.3 2.64 interleukin 6 (interferon, beta 2)
231779_at 2584.4 768.0 2.30 interleukin-1 receptor-associated kinase 2
202859_x_at 348.8 135.7 2.14 interleukin 8
221404_at 1641.2 866.7 2.00 interleukin 1 family, member 6 (epsilon)
208771_s_at 13123.1 8115.0 1.87 leukotriene A4 hydrolase
206295_at 4809.5 2367.4 1.87 interleukin 18 (interferon-gamma-inducing factor)
233011_at 5088.5 2337.0 1.74 annexin A1
207008_at 927.1 515.6 1.74 interleukin 8 receptor, beta
207072_at 196.1 118.2 1.74 interleukin 18 receptor accessory protein
209499_x_at 81.9 57.2 1.74 tumor necrosis factor (ligand) member 13
203140_at 3313.6 2193.9 1.62 B-cell CLL/lymphoma 6 (zinc finger protein 51)
205291_at 536.3 444.7 1.62 interleukin 2 receptor, beta
202688_at 3034.4 1392.6 1.62 tumor necrosis factor (ligand) superfamily, member 10
207817_at 16.7 15.9 1.62 interferon, omega 1
200759_x_at 2230.3 1321.0 1.52 nuclear factor (erythroid-derived 2)-like 1
205185_at 46702.0 30629.6 1.52 serine protease inhibitor, Kazal type 5
219403_s_at 2089.6 1591.4 1.52 heparanase
222484_s_at 5301.6 3222.6 1.52 chemokine (C-X-C motif) ligand 14
Biopsy specimens were taken from the mucosa at 5 mm above the esophagogastric junction. The GeneChip of human
genome U133 Plus 2.0 array (Affymetrix), which contained 54675 probes selected from the UniGene database, was
used to analyze gene expression.
There were detected 844 probes that showed a more than 1.5-fold upregulation in expression between normal control
(n = 3) and NERD patients (n = 3)
Upregulated genes related to cytokines in NERD patients are shown in this table.Oxidative Stress in GERD
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between reflux esophagitis and Barrett’s esophagus by
focusing on cytokine expression. They reported that the
severity of reflux esophagitis was correlated with the
inflammatory cell infiltration score, while IL-1β, IL-8, and
interferon-γ (IFN-γ) were expressed more strongly in the
esophageal mucosa of patients with reflux esophagitis
accompanied by inflammatory cell infiltration than in the
mucosa of those without inflammatory cell infiltration or
those with Barrett’s esophagus. In patients with Barrett’s
esophagus, expression of these acute phase cytokines was
weak, but the expression of IL-10 (an anti-inflammatory
cytokine) and IL-4 (which is known to increase in Th2-
dominant inflammation) was elevated. IL-4 protects the
mucosa by inducing intestinal metaplasia with goblet cells
[8] and by suppressing neutrophil infiltration [9]. Although it
has been assumed that intestinal metaplasia in Barrett’s eso-
phagus is an adaptive response to chronic gastroesophageal
reflux [10], the differences of chemokine expression, especially
IL-4, between patients with reflux esophagitis and those
with Barrett’s esophagus may influence the development of
intestinal metaplasia in the esophagus. It seems likely that
the expression of various cytokines in the esophageal mucosa
causes oxidative stress by inducing the infiltration and
activation of inflammatory cells, as well as by increasing the
production of reactive oxygen species.
Detection of lipid peroxides, and the expression and
activity of antioxidant enzymes have long been used as
indexes of oxidative stress.
It has been reported that an increase of chemiluminescence
and lipid peroxides can be observed in the esophageal
mucosa of patients with reflux esophagitis or Barrett’s
esophagus, depending on the severity of their symptoms,
indicating that free radicals/active oxygen species are
involved in the pathogenesis of reflux esophagitis [11, 12]. It
has also been reported that patients with GERD show an
increase of superoxide dismutase (SOD), an antioxidant
enzyme, in the esophageal mucosa, although the activity
of this enzyme is decreased due to nitration of tyrosine
residues. This indicates that there are elevated levels of
free radicals and peroxynitrite in the esophageal mucosa
of these patients [13]. Furthermore, a decreased glutathione
concentration and an increase of DNA damage have
been observed in the esophageal mucosa of patients
with esophagitis, Barrett’s epithelium, dysplasia, or adeno-
carcinoma, and these two changes show an inverse
correlation [14]. This observation indicates that oxidative
stress is not only involved in the development of mucosal
inflammation, but also has a role in esophageal carcino-
genesis.
Antireflux surgery has recently been performed for the
prevention and treatment of GERD. Evaluation of 20 patients
who underwent antireflux surgery showed that the operation
normalized reflux symptoms and 24-hour pH monitoring,
but it did not completely abolish intramucosal neutrophil
infiltration (MPO activity) or restore the decreased mucosal
levels of reduced glutathione [15]. In addition, the authors of
this report stated that antireflux surgery is unlikely to pre-
vent the development of adenocarcinoma of the esophagus
because it does not improve intramucosal DNA damage
[16]. It is impossible to prevent exposure of oxidative stress
to the esophageal mucosa by antireflux surgery alone.
Chemokine production by esophageal epithelial cells
Although neutrophils infiltrating into the epithelium and
vascular endothelial cells have generally been considered
to be the sources of IL-8 in the esophageal mucosa, our
immunostaining study with an anti-IL-8 monoclonal anti-
body revealed that esophageal epithelial cells in the basal
layer and the lower spinous layer are also an important
source of IL-8 [4]. To investigate the mechanism of IL-8
production, cultured normal human esophageal epithelial
cells were stimulated with IL-1β, tumor necrosis factor
(TNF)-α, bile acids (unconjugated>conjugated), and trypsin
and it was found that the expression of both IL-8 mRNA and
protein was increased through the actions of the transcription
factors NFκB and AP-1 [17, 18]. Interestingly, our data
revealed that conjugated bile acids in acidic media resulted
in remarkable increase in IL-8 production compared with
those in neural −pH media. As mentioned above, the super-
ficial pre-epithelial defenses of the esophagus, such as muco-
protein, are known to be inadequate to protect the epithelium
against various stimulants, and esophageal epithelial cells
are directly exposed to refluxed gastric acid and bile acid.
Esophageal epithelial cells may play an important role in the
initial phase of the development of inflammation. Jenkins et
al. [19] examined gene expression using a cDNA array after
simulation of human Barrett’s adenocarcinoma cell lines
with a bile acid (deoxycholic acid). Among the changes of
gene expression observed, the IκB and IL-8 genes were
most markedly upregulated, indicating that NFκB-dependent
IL-8 production stimulated by deoxycholic acid plays an
important role in inflammation.
Inflammatory changes and oxidative stress in animal models
of esophagitis
As mentioned above, studies using human esophageal
mucosa and cultured esophageal cells have demonstrated that
inflammatory cytokines such as IL-8, leukocyte infiltration,
and oxidative stress are all involved in the pathogenesis of
reflux esophagitis [4, 17, 18] (Fig. 4). To investigate the
mechanism in more detail, esophageal mucosal inflammation
has been studied in animal models.
We recently reported on the important role of inflammatory
cytokines and oxidative stress in the development and pro-
gression of esophagitis based on findings obtained in some
animal models of acute and chronic esophagitis. In a ratN. Yoshida
J. Clin. Biochem. Nutr.
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model of acute esophagitis induced by the reflux of gastric
acid and duodenal juice, an increase of inflammatory
cytokines (cytokine-induced neutrophil chemoattractant-1
(CINC-1, IL-8-like chemokine), TNF-α) in the esophageal
mucosa, infiltration of neutrophils and monocytes into the
mucosa and submucosa, and mucosal lipid peroxidation
were observed before the development of visible lesions.
In the same rat model, when the number of circulating
neutrophils was reduced to approximately 10% of normal
by pretreatment with anti-neutrophil serum, oxidative stress
was reduced and significant suppression of esophageal
lesions was observed both macroscopically and histologically
[20]. In a model of chronic esophagitis due to mixed eso-
phagogastroduodenal reflux, the protease inhibitor, camostat
mesilate, significantly reduced trypsin activity in the eso-
phageal lumen, resulting in significant suppression of the
increased expression of CINC-1, cyclooxygenase-2 (COX-
2), and inducible nitric oxide synthase (iNOS) in the eso-
phageal mucosa, as well as improvement of hyperplastic and
inflammatory mucosal changes [21].
It is generally considered that not only reflux of gastric
acid but also reflux of duodenal juice, which makes the
condition difficult to cure, occurs in GERD. It has been
reported that the serum lipid peroxide concentration, protein
carbonyl content, and oxidative damage to lymphocyte DNA
were significantly greater in an animal model involving the
mixed reflux of gastric acid and duodenal juice than in a
model of acid reflux alone [22]. These findings suggest that
inflammatory cytokines, neutrophils, and oxidative stress
induced by the mixed reflux of gastric acid and duodenal
juice (containing bile acids and trypsin) play an important
role in the development of esophagitis.
To investigate the role of oxidative stress in the develop-
ment of esophagitis, many studies have been conducted
using animal models and the published results include data
on changes of antioxidant enzyme activity and the inhibitory
effect of antioxidants on mucosal changes. Wetscher et al.
[23] reported that reduced glutathione was quickly depleted
along with the development of mucosal lesions and lipid
peroxidation in rat models of mixed- and acid-type eso-
phagitis, while these responses were inhibited by free radical
scavenging enzymes such as SOD and catalase. These
observations suggest the important role of reactive oxygen
species in the development of esophagitis [23, 24].
In a study using rabbits, SOD markedly prevented the
development of lesions due to acid reflux esophagitis, but
dimethyl sulfoxide (DMSO, an OH radical-scavenging agent]
was ineffective. This observation suggested a significant
role of superoxide radicals produced by inflammatory cells
in the pathogenesis of esophagitis [25]. On the other hand, in
a rabbit model of mild esophagitis due to reflux of acidic
pepsin, SOD did not inhibit the development of lesions, but
NO synthase was induced in the mucosa and mucosal
lesions became worse after the administration of an NO
synthesis inhibitor. These observations indicate that super-
oxide radicals are not directly involved in the development
of mucosal lesions, while NO plays an important role in
protecting the esophageal mucosa [26].
Oh et al. [27] reported that a new antioxidant improved
mucosal lesions in a model of mixed esophagitis by signifi-
cantly inhibiting an increase of mucosal lipid peroxide,
activation of NFκB, and decrease of reduced glutathione.
Lee  et al. [28] also suggested that antioxidants may not
only prevent esophageal inflammation but also prevent the
development of Barrett’s esophagus by inhibiting excessive
cell proliferation. Chen et al. [29] used esophagoduodenal
anastomosis to create a rat model of esophagitis in which
iron supplementation considerably enhanced oxidative damage
to DNA, protein, and lipid, and also induced the develop-
ment of inflammation and esophageal adenocarcinoma. In a rat
model of esophagitis that was created using esophagojejunal
anastomosis, administration of SOD decreased mucosal super-
oxide and peroxynitrite levels, increased the mucosal SOD
level, suppressed oxidative damage to DNA, and reduced the
risk of esophageal adenocarcinoma or the risk of intestinal
metaplasia spreading beyond the anastomotic region [30].
These reports indicate that, as observed in studies using
clinical specimens, oxidative stress is involved in the develop-
ment of esophageal inflammation, Barrett’s epithelium, and
esophageal adenocarcinoma in animals (Fig. 5).
It has long been considered that reflux of gastric contents
Fig. 4.  Esophageal mucosal injury mediated by IL-8/oxidative
stress. Production of IL-8 by esophageal epithelial cells
is induced by reflux of bile acids with gastric acid or
trypsin, and mucosal injury is caused by neutrophil-
dependent oxidative stress. Agents that inhibit acid
secretion (e.g., proton pump inhibitors: PPIs), mucosal
protective agents (e.g., rebamipide), and protease
inhibitors are expected to prevent or improve esophageal
inflammation by reducing oxidative stress via various
mechanisms of action.Oxidative Stress in GERD
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due to relaxation of the lower esophageal sphincter (LES)
plays an important role in the development of reflux
esophagitis. Cheng et al. reported that in a cat model of
hydrochloric acid reflux, hydrogen peroxide was induced by
an increase of IL-1 in the LES, after which it inhibited the
release of acetylcholine from cholinergic nerve terminals
and caused LES relaxation by stimulating the synthesis of
prostaglandin (PG) E2 and platelet-activating factor (PAF)
[31,  32]. In addition, hydrogen peroxide seems to be
involved in the mechanism of LES relaxation by inhibiting
both the influx of calcium into cells and mobilization from
calcium stores [33]. In another study on the effects of
exposure to acid using esophageal sections including the
mucosa and muscle coat [34], IL-1 and IL-6 were found
to induce hydrogen peroxide, which was involved in the
contraction of the esophageal muscle coat. The authors also
performed the same series of studies using human LES
tissues. They concluded that mucosal inflammation induced
hydrogen peroxide production, which stimulates the synthesis
of PAF and PGE2 and is involved in LES relaxation [35].
These reports are interesting in that the authors demon-
strated an important role of oxidative stress in reflux due to
impaired LES function.
Acid- and Protease-Sensitive Receptors and Neuro-
peptides in the Esophageal Hypersensitivity: Tran-
scriptome Analysis of Neurogenic Inflammation
Studies of cytokines have revealed that even patients with
NERD may have mild mucosal inflammation, but cytokine
expression is not necessarily associated with the severity of
symptoms such as heartburn [3, 4, 5]. Patient with NERD are
known to show a worse response to PPI therapy than those
with endoscopically positive GERD in terms of symptomatic
improvement. However, the factors associated with the
severity of symptoms in NERD patients are unknown. It was
recently reported that patients with GERD, especially those
with NERD, may have increased esophageal sensitivity.
Trimble  et al. [ 36] reported that when a balloon was
inflated at the mid-esophagus of patients with NERD and
normal subjects, the patients began to feel pain after less air
was added compared with normal subjects. This observation
indicates that NERD patients are more sensitive to pressure.
Miwa et al. [37] reported that NERD patients felt stronger
pain after minimal acid exposure to the esophageal mucosa
and it occurred more rapidly than in those with endo-
scopically positive GERD or normal subjects.
It seemed to us that the greater esophageal sensitivity of
NERD patients might be associated with an abnormality of
receptors for refluxed substances, such as gastric acid and
trypsin, in the esophageal mucosa or an abnormality of
neuropeptides involved in the perception of pain, such as
substance P. We examined gene and protein expression in
endoscopic biopsy specimens by DNA microarray, real-time
PCR, and immunostaining. As a result, the mucosal levels of
transient receptor potential vanilloid receptor subtype 1
(TRPV1: a capsaicin-, heat-, and acid-sensitive ion channel),
protease-activated receptor 2 (PAR2: a receptor for trypsin),
substance P, which is secreted by TRPV1- and PAR2-
positive nerves, and the NK1 receptor (a receptor for
substance P) were significantly higher in NERD patients
than in normal subjects [5]. Because NERD patients have
higher levels of acid and trypsin receptors in the esophageal
mucosa, they may develop edema due to enhanced vascular
permeability resulting from a local increase of substance P
after the activation of these receptors and pain sensations
may be transmitted by substance P-positive nerve fibers
arising from the dorsal nerve root ganglion of the spine.
We need to perform further investigations into the impor-
tant role of receptors/neuropeptides in the development
of symptoms in patients with NERD and GERD, e.g., a
comparative analysis of pretreatment and post-treatment
symptoms (Fig. 6). In addition to analysis of esophageal
mucosal changes, it is necessary to investigate the disease from
various aspects, such as analysis of sensory abnormalities in
the context of the esophagus-brain relationship and analysis
of psychological factors.
Treatment of Esophagitis by Targeting Inflammation
and Oxidative Stress
PPIs: Beyond the acid suppression
PPIs have been widely used for the treatment of acid-
related diseases, such as gastroesophageal reflux disease, as
well as for H. pylori eradication therapy, because of a strong
inhibitory effect on acid secretion. It has recently been
demonstrated that PPIs also have other effects beyond the
suppression of acid secretion [38–45].
We have reported that inactive forms of lansoprazole and
omeprazole circulating in the blood suppressed important
aspects of the acute inflammatory response, such as the
Fig. 5.  Oxidative stress-related esophageal disease. Oxidative
stress induced by reflux of gastric acid and duodenal
fluid (bile acid and pancreatic juice) into the esophagus
is associated with the development of inflammation and
cancer.N. Yoshida
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adhesion of neutrophils to the endothelium and extravascular
migration of neutrophils, by inhibiting the expression of
CD11b/CD18 (a neutrophil adhesion molecule) and by
inhibiting IL-8 synthesis in gastric mucosal epithelial cells
and endothelial cells [39, 45]. These substances are expected
to reduce the infiltration of inflammatory cells (lymphocytes
and monocytes) related to chronic inflammation by in-
hibiting the expression of intercellular adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-
1) on endothelial cells [39]. An important point is that these
effects are observed at serum levels achieved by the clinical
dosage (10−5–10−6 M) but not those that would be needed for
histamine receptor antagonists, though they are also acid
secretion inhibitors. Furthermore, it has been reported that
PPIs inhibit free radical production by neutrophils [40, 41]
and block neutrophil degranulation [40], though at relatively
high concentrations (10−4–10−5 M).
Taken altogether, these evidences suggest that PPIs not
only inhibit acid secretion but also reduce inflammation and
oxidative stress in the gastric and esophageal mucosa by
inhibiting the activation of neutrophils and endothelial cells.
Actually, in our study described above [4], PPI therapy
rapidly reduced IL-8 levels in the human esophageal
mucosa. In an animal model of chronic esophagitis due to
acid reflux, PPI therapy markedly inhibited the expression
of adhesion molecules and inflammatory cytokines in the
esophageal mucosa [42]. In addition, it has been shown
that lansoprazole markedly inhibits small intestinal injury
associated with the increase in cytokines and neutrophils
induced by ischemia/reperfusion or non-steroidal anti-
inflammatory drugs (NSAID), which are unrelated to acid
secretion [43, 44]. These observations suggest that part of
the anti-inflammatory effect of PPIs does not result from the
inhibition of acid secretion. In fact, we have demonstrated
that the anti-inflammatory and anti-oxidant effects of PPI
are partly related to suppression of intracellular calcium
metabolism and to blocking the activation of transcription
factors [45]. Further non-clinical and clinical investigations
into the mechanism of the anti-inflammatory actions of PPI
are needed.
Mucosal protective agents
It has long been known that some gastric mucosal pro-
tective agents have anti-inflammatory and anti-oxidant effects.
In particular, rebamipide shows a variety of anti-inflammatory
actions, such as scavenging of free radicals, inhibition of
ROS and protease production by neutrophils, inhibition of
adhesion molecule expression, and inhibition of cytokine
production [46, 47, 48]. We previously reported that in a rat
model of mixed reflux esophagitis, intraduodenal rebamipide
significantly inhibited the increased expression of mRNA
and protein for CINC-1 and TNF-α, as well as neutrophil
infiltration and lipid peroxidation in the esophageal mucosa
[49], and consequently prevented the development of
mucosal lesions both histologically and macroscopically.
Further investigations are needed regarding the efficacy of
mucosal protective agents for the prevention of esophagitis.
PAR and protease inhibitor
Although the reflux of acid, bile acids, and proteases (such
as trypsin) in pancreatic juice seems to play an important role
in the development of GERD, especially postgastrectomy
damage to the esophageal mucosa, the details of the mecha-
nism involved are unknown.
It has recently been revealed that serine proteases, such
as trypsin and thrombin, are involved in a wide range of
biological responses, such as inflammation, angiogenesis,
cell proliferation, and apoptosis, by activating intracellular
signaling cascades through the PAR [50]. PAR is a seven
transmembrane trimer-G-protein-coupled receptor that is
activated by a specific protease. Of the four family
members, PAR1, PAR3, and PAR4 are primarily activated
by thrombin while PAR2 is activated by trypsin, mast cell
tryptase, and clotting factors VIIa and Xa. We have demon-
strated in an animal model of colitis and a model of human
chronic ulcerative colitis that PAR activation by mast cell-
derived tryptase is involved in the development of colitis
and that anti-PAR therapy based on inhibition of tryptase is
effective for the treatment of colitis [51, 52].
We recently demonstrated that PAR2 is strongly expressed
by normal human esophageal epithelial cells and that PAR-
mediated NFκB-dependent production of IL-8 is induced by
Fig. 6.  Acid/protease-sensitive receptors and neuropeptides in
the hypersensitivity of NERD patients. Substance P
associated with increased expression of transient receptor
potential vanilloid receptor subtype 1 (TRPV1) and
protease-activated receptor 2 (PAR2) may be involved
in the development of hypersensitivity of NERD patients.Oxidative Stress in GERD
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stimulation with trypsin [18]. In addition, camostat mesilate,
a protease inhibitor clinically used for the treatment of post-
gastrectomy reflux esophagitis, dose-dependently suppressed
IL-8 production by inhibiting the activity of trypsin (Fig. 7).
Because of its inhibitory effect on protease activity, camostat
mesilate is expected to improve esophagitis by reducing
cytokine production resulting from the PAR-mediated
activation of esophageal epithelial cells as well as oxidative
stress due to the infiltration of inflammatory cells.
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